PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells |
| |
Authors: | ZAHRA NASRPOUR NAVAEI GHAZALEH KHALILI-TANHA AMIR SADRA ZANGOUEI MOHAMMAD REZA ABBASZADEGAN MEYSAM MOGHBELI |
| |
Institution: | 1 Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran2 Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran3 Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran |
| |
Abstract: | Chemotherapy is one of the main therapeutic modalities for cancer patients. Cisplatin (CDDP), as one of the
first-line drugs, is of great importance in the chemotherapy of various tumors. However, a significant percentage of cancer
patients are resistant to CDDP treatment. Due to the CDDP side effects on normal tissues, the diagnosis of CDDP
resistance is required to suggest the most efficient therapeutic strategies for cancer patients. Several molecular
mechanisms and signaling pathways are associated with CDDP response. The PI3K/AKT signaling pathway has a
pivotal role in the transmission of extracellular signals into the cells to regulate various pathophysiological processes
such as cell proliferation, migration, and drug resistance. In the present review, we summarized all of the studies
which have been reported on the role of PI3K/AKT pathway in regulation of CDDP response. It was shown that the
PI3K/AKT pathway is mainly involved in CDDP response in lung, ovarian, and gastrointestinal cancers. It was also
observed that the non-coding RNAs have a key role in CDDP response by regulation of PI3K/AKT pathway. This
review paves the way for suggesting a PI3K/AKT-related panel marker for the prediction of CDDP response in
different cancer patients. |
| |
Keywords: | PI3K/AKT Cancer Chemoresistance Cisplatin Chemotherapy |
|
| 点击此处可从《Oncology research》浏览原始摘要信息 |
| 点击此处可从《Oncology research》下载免费的PDF全文 |
|